THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

THE EVIDENCE-GRADED DIRECTORY

The Peptide Atlas.

Educational only. Not prescribing guidance or a treatment offer. Keep searches educational, not personal.
Filters & sort

Showing 6 of 30 profiles

All learning goals · Evidence grades are not treatment rankings.

FDA-approvedHigh for approved indication
Illustrative Semaglutide vial concept
THE MODERN BIOSemaglutide

Metabolic & fat loss

Semaglutide

A GLP-1 receptor agonist with strong outcome data for defined metabolic indications.
KEY LIMIT

A universal weight-loss drug for anyone wanting to be leaner

3 direct source links2 research searches
FDA-approvedHigh for approved indication
Illustrative Tirzepatide vial concept
THE MODERN BIOTirzepatide

Metabolic & fat loss

Tirzepatide

A dual GIP/GLP-1 peptide agonist with strong evidence for obesity and type 2 diabetes.
KEY LIMIT

That higher dose is always better

2 direct source links2 research searches
FDA-approvedHigh for approved indication
Illustrative Liraglutide vial concept
THE MODERN BIOLiraglutide

Metabolic & fat loss

Liraglutide

A daily GLP-1 peptide with established metabolic indications and longer real-world history.
KEY LIMIT

That it should be combined with another GLP-1 drug

2 direct source links1 research searches
FDA-approvedHigh for approved indication
Illustrative Tesamorelin vial concept
THE MODERN BIOTesamorelin

Metabolic & fat loss

Tesamorelin

Approved for excess abdominal fat in adults with HIV lipodystrophy—not general weight loss.
KEY LIMIT

General obesity treatment

2 direct source links0 research searches
FDA-approvedHigh for approved indication
Illustrative Setmelanotide vial concept
THE MODERN BIOSetmelanotide

Metabolic & fat loss

Setmelanotide

A diagnosis-specific obesity therapy for selected rare disorders and acquired hypothalamic obesity.
KEY LIMIT

Use for ordinary obesity

1 direct source links0 research searches
InvestigationalLate-stage human
Illustrative Retatrutide vial concept
THE MODERN BIORetatrutide

Metabolic & fat loss

Retatrutide

A triple GIP/GLP-1/glucagon agonist in clinical development—not an approved drug.
KEY LIMIT

Long-term benefit-risk outside trials

6 direct source links0 research searches

Vial images are illustrative concepts, not products offered for sale or evidence of approval or availability.

Compare the evidence

Select up to 3 profiles. Selection is preserved when you change filters.

View comparison (0/3) ↓

YOUR LEARNING STARTING POINT

What do you want to understand?

Choose an area to explore. This changes your reading path, not a treatment recommendation.

No health history needed. Filters and comparison choices appear in the shareable page URL, not your account. Keep search terms educational; do not enter personal health details.

SIDE BY SIDE

The differences that matter.

Compare the research context, not which peptide you should take. Studies may involve different conditions and populations; this is not a head-to-head trial or a safety ranking.

Use “+ Compare” on any profile above to build your comparison.

TAKE THE NEXT USEFUL STEP

Leave with better questions.

Ask what was studied, what remains unknown and whether a better-established option fits the clinical question.

  • Does the evidence match the condition, population and product?
  • What are the important risks, interactions and alternatives?
  • Who is responsible for evaluation and follow-up?
Read our care and evidence boundaries →
OUR SCOPE

“Available” does not mean approved—or proven.

This atlas covers peptides commonly marketed in the U.S. biohacking, telehealth, cosmetic and research-chemical ecosystem, plus clinically important approved peptide therapies. It is not every peptide drug used across all of medicine. Profiles carry their own recorded review dates. Some content dates to July 2026; this is not a continuously verified regulatory database. Check the linked official record before relying on an approval or access claim.

Abstract visualization of metabolic and recovery signaling
01Metabolism & recoverySignals that affect appetite, growth, repair and body composition.
Abstract visualization of collagen and mitochondrial biology
02Skin & longevityCollagen, cellular energy and healthy-aging research.
Abstract visualization of neural and immune signaling
03Brain & immune signalingNeural, sleep, inflammatory and neuroendocrine pathways.

HOW TO USE THIS PAGE

Separate approved medicine from promising research and online marketing.

  1. 01
    Start with the goal

    Choose the clinical or performance question before choosing a molecule.

  2. 02
    Check status and evidence

    Approval, human evidence, formulation and dose context are separate questions.

  3. 03
    Prepare a clinician brief

    Bring the exact product, claim, risks, monitoring plan and safer alternatives into the conversation.

0130DETAILED PROFILES
027HEALTH CATEGORIES
0310FDA-APPROVED PEPTIDES*
0415NOT FDA-APPROVED

*Approval applies only to the specific indication, formulation, population and dose described in the prescribing information—not every wellness claim attached to the molecule.

01 / BROWSE BY GOAL

Start with the outcome.
Then check the status.

The same peptide can appear in several marketing categories. We place it where consumers most commonly encounter it and explain the boundaries on its profile.

STATUS KEY

Four labels that change the entire conversation.

FDA-approvedReviewed product, narrow claim.

FDA reviewed a specific product for a specific indication. Off-label wellness claims may still be unsupported.

InvestigationalHuman research, not market authorization.

Legitimate access may be limited to registered clinical trials.

Food supplement / cosmeticDifferent rules and expectations.

Topical or oral consumer use does not establish injectable safety.

Not FDA-approvedNo FDA-reviewed safety, efficacy or quality.

Being sold online or compounded does not make a product approved.

02 / READ THE RESEARCH

A promising mechanism is not a proven outcome.

Our evidence labels follow the drug-development path: laboratory signals can justify human research, but well-designed clinical studies are needed to evaluate benefits and harms. A label is not a score for every claim made about a molecule.
01PRECLINICALCells and animals

Useful for mechanism and toxicity questions. It cannot establish a consumer treatment.

02PHASE 1First human signal

Usually explores safety, pharmacology and dose—not whether a wellness claim works.

03PHASE 2Early efficacy

Tests the intervention in people with the target condition and continues safety work.

04PHASE 3Confirmation

Larger studies test whether benefits hold up against a comparator and reveal more harms.

05FDA + AFTERSpecific approval

Review applies to a defined product, indication and label; monitoring continues after launch.

How to read our labels

Evidence grades are editorial summaries for the context described, not a formal systematic review or clinician endorsement. Approval and evidence certainty are separate: accelerated approval can rely on an intermediate endpoint, with confirmatory evidence still required. Source counts include different kinds of links and are not a quality score.

04 / REAL-WORLD CHECKS

Research does not end at the molecule.

Product identity, pharmacy legitimacy, sport rules and adverse-event reporting can matter as much as the headline claim.

Competitive-sport rules change and can be substance-, route- and timing-specific. The 2026 WADA Prohibited List is in force; Global DRO is a medication-status reference, not a substitute for your anti-doping organization.

BEFORE ANY PEPTIDE

Verify five things before a needle ever enters the conversation.

  1. 01Exact identity

    Brand, molecule, salt or analog, concentration, route and lot.

  2. 02Regulatory status

    Approved product, lawful compounding need, clinical trial or gray market.

  3. 03Human evidence

    Meaningful outcomes in people—not only animal mechanisms or testimonials.

  4. 04Clinical fit

    Diagnosis, contraindications, medication interactions and monitoring plan.

  5. 05Exit criteria

    What success means, when to reassess and which symptoms mean stop.

MODERN BIO / ADVANCED THERAPIES / PEPTIDES

THE EVIDENCE-GRADED DIRECTORY

The Peptide
Atlas.

Know what is medicine,
what is research and what is marketing.

A field guide to the peptides most often discussed in metabolic health, recovery, skin, energy, cognition, sexual health and immune care—with evidence limits, risks and linked references.

Explore 30 peptide profiles
Abstract scientific illustration of cellular structures and molecular signals
A CLOSER LOOKEvidence before expectation.Conceptual scientific illustration

01 / EXPLORE THE ATLAS

Start with your question.

Choose a learning goal, filter the evidence and compare up to three profiles. Every profile separates what is known from what remains uncertain.

THE MODERN BIO STANDARD

We will never sell certainty where the evidence is uncertain.

Approved therapies may earn a vetted treatment pathway. Unapproved research peptides will not receive a “best product” recommendation simply because a vendor sells them.Get research updates →

YOUR NEXT STEP

Ready for a clinician-led plan?

Clinical review determines the appropriate next step. No treatment is guaranteed.

THE CARE PATH

  1. We order your labs

  2. A licensed clinician reviews results and recommends a plan

  3. Rx sent directly to you when appropriate

Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.

Start your lab reviewExplore free educational tools
Education you can use now.The Atlas is free to explore. It does not assess eligibility, provide prescriptions or confirm treatment availability through Modern Bio.Our standards →